Equities Analysts Set Expectations for FibroGen Q1 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for FibroGen in a research report issued to clients and investors on Tuesday, April 1st. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

A number of other equities analysts have also commented on FGEN. StockNews.com assumed coverage on shares of FibroGen in a report on Sunday. They issued a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Trading Up 2.0 %

NASDAQ FGEN opened at $0.31 on Thursday. The company’s fifty day simple moving average is $0.45 and its 200-day simple moving average is $0.43. The stock has a market cap of $30.90 million, a P/E ratio of -0.25 and a beta of 0.82. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.15.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million.

Insider Activity at FibroGen

In other news, CEO Thane Wettig acquired 145,000 shares of FibroGen stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $0.35 per share, for a total transaction of $50,750.00. Following the completion of the purchase, the chief executive officer now directly owns 543,329 shares of the company’s stock, valued at $190,165.15. This trade represents a 36.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James A. Schoeneck bought 250,000 shares of the stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the purchase, the director now owns 323,722 shares of the company’s stock, valued at $113,302.70. The trade was a 339.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On FibroGen

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in shares of FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the period. Renaissance Technologies LLC increased its position in FibroGen by 80.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares during the period. Mackenzie Financial Corp increased its position in FibroGen by 416.6% in the fourth quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 441,083 shares during the period. Squarepoint Ops LLC bought a new stake in FibroGen in the fourth quarter valued at $205,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after acquiring an additional 135,600 shares during the period. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.